Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: UROKINASE-TYPE PLASMINOGEN ACTIVATOR - METABOLISM, . Treffer: 5
2022
Singer, CF; Jahn, SW; Rudas, M; Bago-Horvath, Z; Fitzal, F; Abete, L; Moinfar, F; Gnant, M; Filipits, M, , Austrian, Breast, and, Colorectal, Cancer, Study, Group, (ABCSG)
Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry.
Breast. 2022; 64:127-133
Doi: 10.1016/j.breast.2022.05.003
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Santibanez, JF; Obradović, H; Kukolj, T; Krstić, J
Transforming growth factor-β, matrix metalloproteinases, and urokinase-type plasminogen activator interaction in the cancer epithelial to mesenchymal transition.
Dev Dyn. 2018; 247(3):382-395
Doi: 10.1002/dvdy.24554
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Krstić, J; Obradović, H; Jauković, A; Okić-Đorđević, I; Trivanović, D; Kukolj, T; Mojsilović, S; Ilić, V; Santibañez, JF; Bugarski, D
Urokinase type plasminogen activator mediates Interleukin-17-induced peripheral blood mesenchymal stem cell motility and transendothelial migration.
Biochim Biophys Acta. 2015; 1853(2): 431-444.
Doi: 10.1016/j.bbamcr.2014.11.025
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2013
Kocić, J; Santibañez, JF; Krstić, A; Mojsilović, S; Ilić, V; Bugarski, D
Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase.
Int J Biochem Cell Biol. 2013; 45(2): 464-475.
Doi: 10.1016/j.biocel.2012.11.010
Web of Science
PubMed
FullText
FullText_MUG
2010
Villar, V; Kocić, J; Santibanez, JF
Spred2 inhibits TGF-beta1-induced urokinase type plasminogen activator expression, cell motility and epithelial mesenchymal transition.
Int J Cancer. 2010; 127(1): 77-85.
Doi: 10.1002/ijc.25045
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG